Acrivon Reports Strong Clinical Data for ACR-368 & ACR-2316, Secures Breakthrough Device Designation, and Extends Cash Runway

summarizeSummary

Acrivon Therapeutics reported strong clinical data for ACR-368 in endometrial cancer, initial positive activity for ACR-2316, and secured a cash runway into Q2 2027, alongside receiving Breakthrough Device Designation for its OncoSignature assay.

check_boxKey Events

• Strong Clinical Data for ACR-368 in Endometrial Cancer

  Interim data from the registrational intent Phase 2b trial of ACR-368 in endometrial cancer showed a 35% confirmed overall response rate (ORR) and 80% tumor shrinkage in OncoSignature-positive patients. In serous EC patients with up to two prior lines of therapy, the confirmed ORR was 52% across pooled biomarker-positive and negative subjects, and 67% in biomarker-positive serous EC subjects.

• Breakthrough Device Designation for OncoSignature Assay

  The FDA granted Breakthrough Device Designation to the ACR-368 OncoSignature assay for identifying endometrial cancer patients who may benefit from ACR-368 treatment, following a similar designation for ovarian cancer.

• ACR-2316 Phase 1 Shows Initial Clinical Activity

  The internally discovered WEE1/PKMYT1 inhibitor, ACR-2316, demonstrated initial clinical activity with tumor shrinkage in 9 out of 20 evaluable patients in its Phase 1 trial, including confirmed partial responses in EC, SCLC, and sqNSCLC.

• Extended Cash Runway into Q2 2027

  The company reported $118.6 million in cash, cash equivalents, and investments as of December 31, 2025, which is expected to fund operations and capital expenditures into the second quarter of 2027.

auto_awesomeAnalysis

Acrivon Therapeutics' 10-K filing reveals significant advancements in its clinical pipeline and regulatory strategy. The company reported compelling interim data from its registrational intent Phase 2b trial for ACR-368 in endometrial cancer, showing high confirmed overall response rates, which is a critical positive for a clinical-stage biotech. The FDA's Breakthrough Device Designation for the ACR-368 OncoSignature assay is a key regulatory milestone, potentially accelerating the development and approval of this crucial companion diagnostic. Additionally, initial clinical activity observed for ACR-2316 in its Phase 1 trial provides early validation for their proprietary AP3 platform. Financially, the company has extended its cash runway into the second quarter of 2027, providing essential operating capital, though it continues to incur substantial losses and will require further funding. The recent cashless exercise of 7.06 million pre-funded warrants, while dilutive, was a component of a prior capital raise that contributed to this extended runway. The termination of the Akoya agreement and bringing CLIA operations in-house is a strategic move to gain full control over diagnostic development, which could streamline future processes.